Heritage issues recall after products contaminated with ‘microbial growth’

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Barbol88)
(Image: Getty/Barbol88)

Related tags Heritage Pharmaceuticals Emcure Pharmaceuticals India

Heritage announces a recall of lots of amikacin sulfate injection and prochlorperazine edisylate injection, due to evidence of selected products being non-sterile.

The recall was announced by US company, Heritage Pharmaceuticals, on Saturday​ for the two products when two unreleased lots were found to be non-sterile and intended for the consumer market in the US.

The products, amikacin sulfate injection, 1g/4 mL, and prochlorperazine edisylate injection, 10mg/2mL, are manufactured by Emcure Pharmaceuticals, a company headquartered in India, while Heritage distributes the products across the US market.

In its announcement, Heritage stated that the recall was issued “due to microbial growth having been detected”​ in two separate lots of the medicines.

As a result, the company noted that this may indicate a ‘lack of sterility’ in other sublots of the products.

A patient who was administered a non-sterile injectable product could potentially contract a site-specific or system infection, leading to hospitalisation, organ damage or death, the company added.

At the time of the recall, Heritage had not received any reports of adverse events regarding patients who had received the products.

Amikacin sulfate injection is used for the treatment for serious infections due to gram-negative bacteria, and prochlorperazine edisylate injection is used to control severe nausea, as well as schizophrenia.

Both of the affected lots were delivered to distributors and wholesalers mid-way through last year, with the amikacin sulfate injection being released between June 2018 and August 2018, and the prochlorperazine edisylate injection between October 2018 and November 2018.

The recall is unfortunate for Emcure, which suffered a dent to its reputation when the US Food and Drug Administration (FDA) banned imports from Emcure’s Pune, India​, facility after inspections discovered good manufacturing practice (GMP) deficiencies were revealed in 2016.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more